Price Alert

Halozyme Therapeutics Inc... (HALO)

NASDAQ: HALO · Real-Time Price · USD

67.28

1.74 (2.65%)

At close: Aug 15, 2025, 3:59 PM

67.50

0.33%

After-hours: Aug 15, 2025, 07:58 PM EDT

Halozyme Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021
Revenue	325.72M	264.86M	298.01M	290.08M	231.35M	195.88M	230.04M	216.03M	221.04M	162.14M	181.5M	208.98M	152.37M	117.28M	102M	115.83M	136.46M	89.02M
Cost of Revenue	46.36M	48.4M	42.05M	49.43M	57.37M	46.09M	52.3M	54.82M	50.07M	35.17M	42.12M	47.32M	33.94M	15.92M	21.59M	18.59M	23.02M	18.22M
Gross Profit	279.36M	216.46M	255.95M	240.66M	173.98M	149.79M	177.74M	161.21M	170.97M	126.97M	139.38M	161.66M	118.42M	101.36M	80.42M	97.24M	113.44M	70.8M
Operating Income	202.44M	141.53M	175.5M	163.2M	117.23M	95.54M	101.03M	88.28M	94.46M	53.8M	74.51M	83.29M	34.06M	75.67M	56.53M	75.59M	93.05M	50.73M
Interest Income	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Pretax Income	204.94M	143.83M	178.21M	165.15M	117.74M	96.03M	101.17M	101.76M	93.16M	52.24M	70.79M	73.71M	30.01M	74.41M	54.81M	74.11M	91.52M	28.09M
Net Income	165.16M	118.09M	137.01M	137.01M	93.25M	76.82M	85.39M	81.84M	74.75M	39.62M	57.7M	61.63M	22.68M	60.11M	66.77M	216.59M	91.46M	27.89M
Selling & General & Admin	41.61M	42.36M	42.25M	41.24M	35.71M	35.13M	37.61M	35.27M	38.95M	37.36M	37.75M	34.47M	57.48M	13.83M	13.77M	13.17M	12.32M	11.06M
Research & Development	17.54M	14.8M	20.44M	18.46M	21.04M	19.11M	21.34M	17.32M	19.73M	17.98M	22.57M	16.7M	15.48M	11.85M	10.11M	8.49M	8.07M	9.01M
Other Expenses	17.76M	17.76M	17.76M	17.76M	n/a	n/a	17.76M	20.34M	17.84M	17.84M	4.55M	27.19M	11.4M	n/a	n/a	n/a	n/a	n/a
Operating Expenses	76.92M	74.92M	80.45M	77.46M	56.75M	54.24M	76.71M	72.93M	76.51M	73.17M	64.87M	78.36M	84.36M	25.69M	23.88M	21.66M	20.39M	20.07M
Interest Expense	4.39M	4.53M	4.54M	4.52M	4.52M	4.51M	5.22M	4.5M	4.49M	4.54M	4.57M	7.51M	3.1M	1.76M	2.06M	1.75M	1.75M	1.97M
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	123.28M	123.33M	122.51M	126.89M	114.12M	100.34M	129M	127.75M	126.58M	108.34M	106.99M	125.68M	118.31M	41.61M	45.47M	40.24M	43.41M	38.29M
Income Tax Expense	39.78M	25.73M	41.2M	28.14M	24.5M	19.2M	15.79M	19.92M	18.4M	12.62M	13.09M	12.07M	7.33M	14.3M	-11.96M	-142.48M	58K	191K
Shares Outstanding (Basic)	121.34M	123.22M	126.41M	126.85M	127.12M	126.94M	129.05M	131.97M	131.73M	135.03M	135.28M	136.53M	137.94M	137.66M	140.22M	142.02M	142.49M	137.95M
Shares Outstanding (Diluted)	124.16M	126.64M	129.42M	130.13M	129.22M	128.89M	131.03M	134.08M	133.54M	137.9M	138.6M	139.39M	142.22M	141.28M	144.25M	146.69M	147.62M	148.54M
EPS (Basic)	1.36	0.96	1.08	1.08	0.73	0.61	0.66	0.62	0.57	0.29	0.43	0.45	0.16	0.44	0.48	1.53	0.64	0.20
EPS (Diluted)	1.33	0.93	1.06	1.05	0.72	0.60	0.65	0.61	0.56	0.29	0.42	0.44	0.16	0.43	0.46	1.48	0.62	0.19
EBITDA	229.83M	168.8M	203.17M	190.03M	137.6M	115.75M	127.09M	129.31M	118.28M	77.24M	82.47M	110.41M	45.62M	76.45M	57.64M	76.56M	94.07M	51.47M
EBIT	209.33M	148.35M	182.75M	169.67M	117.23M	95.54M	106.39M	106.27M	97.65M	56.78M	75.36M	81.22M	33.12M	75.67M	56.87M	75.59M	93.05M	50.73M
Depreciation & Amortization	20.5M	20.45M	20.41M	20.36M	20.36M	20.21M	20.69M	23.04M	20.64M	20.46M	7.11M	29.19M	12.5M	778K	773K	700K	800K	738K